Biomerieux Stock Price, News & Analysis

bioMérieux has launched GENE-UP® TYPER, a real-time PCR solution for rapid pathogen detection and root cause analysis in the food industry. The innovative diagnostic solution helps food manufacturers quickly identify the source of Listeria monocytogenes contamination.

The system combines a specific assay with the AUGMENTED-DX web application, powered by machine learning and a comprehensive genomic database. After pathogen detection and strain isolation, DNA is extracted and amplified, generating analytical results that define unique strain identifiers and group identical strains into clusters. This enables tracking contamination sources and improving production process control.

The solution was developed in collaboration with Mérieux NutriSciences, which will retain co-exclusive rights for testing services. GENE-UP® TYPER LMO, the first assay targeting Listeria monocytogenes, is now available worldwide for food manufacturers.

bioMérieux, a global leader in in vitro diagnostics, has opened its new Molecular and Genomic Innovation Center at the Navy Yard in Philadelphia. The 32,000 sq. ft. facility houses the xPRO™ Program, which focuses on developing innovative food safety diagnostic solutions. The center includes state-of-the-art labs for genomic discovery and research & development, enabling rapid ideation, development, and validation of new assays.

The expansion is part of bioMérieux's Augmented Diagnostics approach, aiming to redefine diagnostic testing capabilities in food safety. The company celebrated the opening with a $10,000 donation to the Science Center's FirstHand™ program, supporting STEM education for students. The new facility strengthens bioMérieux's presence in Philadelphia's thriving life sciences innovation hub and reinforces its commitment to addressing global food safety challenges.

Oxford Nanopore Technologies and bioMérieux have partnered to enhance infectious disease diagnostics using nanopore sequencing technology. This collaboration aims to improve patient care by developing innovative solutions for the rapid identification of pathogens and antibiotic resistance. Initial projects will focus on tuberculosis resistance testing and pathogen detection in clinical samples. With Oxford Nanopore's advanced sequencing capabilities, the partnership seeks to deliver timely and comprehensive diagnostic results, ultimately contributing to better health outcomes globally.

bioMérieux has launched GENE-UP® ENVIROPRO™, a unique assay that detects Salmonella and Listeria from environmental swabbing using a single enriched sample with PCR confirmation. This innovation enhances food safety protocols by reducing costs, minimizing laboratory waste, and streamlining workflows. The product, part of bioMérieux's xPRO program, aims to improve efficiencies in environmental monitoring across various food sectors, including dairy and ready-to-eat meals. With a proven track record and notable prior achievements, the introduction of GENE-UP® ENVIROPRO™ underscores bioMérieux's commitment to innovation in diagnostics.

The ARPEGE project, led by Antabio, has received nearly €9 million in public funding from the French government to combat antibiotic resistance. This initiative addresses an urgent global health threat projected to cause up to 10 million deaths annually by 2050. The four-year project, with a total budget of €17 million, focuses on expanding effective antibiotics, improving diagnostics, preventing bacterial transmission in hospitals, and developing new economic models. Collaborating partners include bioMérieux, Hospitals Civils de Lyon, and Toulouse School of Economics.

Baxter and bioMérieux have announced the CE marking of the NEPHROCLEAR™ CCL14 Test, a diagnostic tool designed to predict persistent severe acute kidney injury (PS-AKI). Expected for commercial launch in western Europe in 2022, the test aims to optimize critical care by helping healthcare providers anticipate the appropriate level of care for AKI patients. CCL14 has been identified as the most predictive biomarker for PS-AKI, with a diagnostic accuracy (AUC) of 0.82, indicating its potential to significantly improve patient outcomes.

Mérieux NutriSciences has launched its digital platform, EnviroMap, a cloud-based system for environmental sampling programs, now available through bioMérieux. This integration allows seamless uploading of real-time results, enhancing decision-making and traceability. The platform aims to improve operational efficiency by offering complete environmental monitoring solutions, reducing errors, and providing early warnings for food safety risks. Mérieux NutriSciences, present in 24 countries, focuses on food safety and quality, while bioMérieux continues to lead in in vitro diagnostics worldwide.